---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-072753"
form_type: "8-K"
ticker: null
cik: "0001621227"
company_name: "Adaptimmune Therapeutics PLC"
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:19:46.110750+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Adaptimmune sells cell therapy assets to US WorldMeds for $55M cash plus $30M milestones

## Summary
- Sold TECELRA, lete-cel, afami-cel, uza-cel to US WorldMeds subsidiary; $55M upfront, up to $30M in milestones.
- Hercules Capital loan of $29.1M paid off, terminating the Loan and Security Agreement.
- Pro forma net gain on sale estimated at $134M after tax; FY2024 pro forma net income of $159.6M vs prior loss.
- Milestones: $5M on lete-cel BLA acceptance, $10M on FDA approval, up to $5M on TECELRA revenue thresholds.
- Pro forma cash increases to $91M from $41M; equity turns positive to $96.7M from negative $37.4M.

## SEC filing metadata
- accession: 0001104659-25-072753
- form_type: 8-K
- cik: 0001621227
- company_name: Adaptimmune Therapeutics PLC
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.02, 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1621227/000110465925072753/0001104659-25-072753-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1621227/000110465925072753/tm2522092d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-072753
- JSON: https://secwatch.observer/filing/0001104659-25-072753.json
- Plain text: https://secwatch.observer/filing/0001104659-25-072753.txt

## Key facts
- M&A Transactions
  Adaptimmune Therapeutics PLC completed a disposition involving USWM CT, LLC, a subsidiary of US WorldMeds Partners, LLC for $55 million in cash upon consummation of the Transaction, and Purchaser has agreed to make future payments of up to $30 million (closed 2025-07-31).
  - Action: disposition
  - Counterparty: USWM CT, LLC, a subsidiary of US WorldMeds Partners, LLC
  - Consideration: $55 million in cash upon consummation of the Transaction, and Purchaser has agreed to make future payments of up to $30 million
  - Closing: 2025-07-31
  source text: rights, regulatory authorizations, contracts, equipment, inventory, and other related assets (together with the Products, the “Transferred Assets”). Purchaser paid Adaptimmune $55 million in cash upon consummation of the Transaction, and Purchaser has agreed to make future payments of up to $30 million to Adaptimmune upon the achievement of certain regulatory and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1621227/000110465925072753/0001104659-25-072753-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.